Search results for "Cox proportional hazards regression"

showing 3 items of 3 documents

Survival and prognostic factors in patients with oral squamous cell carcinoma

2020

Background This study aimed to evaluate sociodemographic and clinical factors influencing overall survival (OS) in patients with oral squamous cell carcinoma (OSCC). Material and Methods Medical charts of 547 patients with OSCC from a public hospital in northeastern Brazil seen between 1999 and 2013 were evaluated. Survival analysis was performed using the Kaplan-Meier method. The influence of age, sex, ethnicity, clinical stage, anatomical location, type of treatment, and comorbidities on the patients’ prognosis was evaluated. Cox proportional hazards regression model was used to identify independent prognostic factors. Results The 5-year OS was 39%. Multivariate analysis showed that age <…

AdultOncologymedicine.medical_specialtyPoor prognosisYounger ageMultivariate analysisneoplasmsglandular and epithelial03 medical and health scienceshead and neck neoplasms0302 clinical medicineOral Cancer and Potentially malignant disordersInternal medicinefollow up studiesCox proportional hazards regressionHumansMedicineBasal cellIn patientStage (cooking)General DentistryUNESCO:CIENCIAS MÉDICASSurvival analysisRetrospective StudiesSquamous Cell Carcinoma of Head and Neckbusiness.industryResearchrare diseases030206 dentistryPrognosisstomatognathic diseasesOtorhinolaryngologyCarcinoma Squamous CellMouth NeoplasmsepidemiologySurgerybusinessBrazilMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

2020

Background &amp; Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (&lt;65, ≥65 to &lt;75 and ≥75 years). Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods …

Sorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinoma[SDV.CAN]Life Sciences [q-bio]/CancerSorafenib intolerancePlaceboAntibodies Monoclonal HumanizedGastroenterologyRamucirumabRamucirumabCàncer de fetge03 medical and health sciences0302 clinical medicineElderlyInternal medicineCox proportional hazards regressionMedicineHumansAgedHepatologyElevated alpha-fetoproteinbusiness.industryPersones grans dependentsHazard ratioLiver Neoplasms[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyHepatitis CSorafenibmedicine.diseaseFrail elderly3. Good healthVEGFR2Treatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030211 gastroenterology & hepatologyMonoclonal antibodiesAlpha-fetoprotein (AFP)alpha-FetoproteinsbusinessAnticossos monoclonalsLiver cancermedicine.drugLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Joint associations of accelerometer-measured physical activity and sedentary time with all-cause mortality: a harmonised meta-analysis in more than 4…

2020

Funder: National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East Midlands

Time Factors2314educationPhysical activityPhysical Therapy Sports Therapy and RehabilitationsedentarydeathAccelerometryCox proportional hazards regressionHumansMedicineOrthopedics and Sports Medicine1506Prospective cohort study1507Exercisehealth care economics and organizationsAgedSedentary timeMortality Prematurebusiness.industryOriginal researchMortality rateGeneral MedicineMiddle AgedVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850Peer reviewmeta-analysisaccelerometerMeta-analysisSedentary BehaviorbusinessAll cause mortalityDemographyBritish Journal of Sports Medicine
researchProduct